Molecular cytogenetics of lymphoma: Where do we stand in 2010?

Histopathology

Volumn 58, Issue 1, 2011, Pages 128-144

  Kluin, Philip ^a   Schuuring, Ed ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cytogenetics; Lymphoma; Review

Indexed keywords

CYANINE DYE 3; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; MESSENGER RNA; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6; RAG1 PROTEIN; RAG2 PROTEIN;

BURKITT LYMPHOMA; CHROMOSOME BREAKAGE; CHROMOSOME PREPARATION; COMPARATIVE GENOMIC HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MOLECULAR GENETICS; MORPHOLOGY; ONCOGENE MYC; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ANIMALS; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETIC ANALYSIS; CYTOGENETICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LYMPHOMA; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 78851470640     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03700.x     Document Type: Review

References (83)

1. World Health Organization (WHO). WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: International Agency for Research on Cancer, 2008.
2. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J. Natl. Canc. Inst. 1960; 25; 85-109.
3. Jacobs PA, Tough IM, Wright DH. Cytogenetic studies in Burkitt's lymphoma. Lancet 1963; 2; 1144-1146.
4. Siebert R. Mature B- and T-cell neoplasms and Hodgkin lymphoma. In Heim S, Mitelman F eds. Cancer cytogenetics, 3rd edn. Chichester: Wiley-Blackwell, 2009; 297-374.
5. Barrans S, Crouch S, Smith A et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J. Clin. Oncol. 2010; 28; 3360-3365.
6. Carbone A, Gloghini A, Aiello A, Testi A, Cabras A. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. Hum. Pathol. 2010; 41; 621-631.
7. Johnson NA, Savage KJ, Ludkovski O et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114; 2273-2279.
8. Hasserjian RP, Ott G, Elenitoba-Johnson KS, Balague-Ponz O, De Jong D, de Leval L. Commentary on the WHO classification of tumors of lymphoid tissues (2008): 'gray zone' lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. J. Hematop. 2009; 2; 89-95.
9. Tomita N, Tokunaka M, Nakamura N et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 2009; 94; 935-943.
10. Le Gouill S, Talmant P, Touzeau C et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007; 92; 1335-1342.
11. Ventura RA, Martin-Subero JI, Jones M et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J. Mol. Diagn. 2006; 8; 141-151.
12. Haralambieva E, Kleiverda K, Mason DY, Schuuring E, Kluin PM. Detection of three common translocation breakpoints in non-Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections. J. Pathol. 2002; 198; 163-170.
13. Boerma EG, Siebert R, Kluin PM, Baudis M. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia 2009; 23; 225-234.
14. Toujani S, Dessen P, Ithzar N et al. High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma. PLoS ONE 2009; 4; e7089.
15. Hummel M, Bentink S, Berger H et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 2006; 354; 2419-2430.
16. Seegmiller AC, Garcia R, Huang R, Maleki A, Karandikar NJ, Chen W. Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. Mod. Pathol. 2010; 23; 909-920.
17. Salaverria I, Zettl A, Bea S et al. Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica 2008; 93; 1327-1334.
18. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dysregulation of cyclin D1 by translocation into IgH gamma switch region in two multiple myeloma cell lines. Blood 1996; 88; 674-681.
19. Janssen JWG, Vaandrager JW, Heuser T et al. Concurrent activation of a novel putative transforming gene, MYEOV, and cyclin D1 is a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood 2000; 95; 2691-2698.
20. Speicher MR, Gwyn BallardS, Ward DC. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat. Genet. 1996; 12; 368-375.
21. Tanke HJ, Wiegant J, van GijlswijkRP et al. New strategy for multi-colour fluorescence in situ hybridisation: COBRA: COmbined Binary RAtio labelling. Eur. J. Hum. Genet. 1999; 7; 2-11.
22. Gisselsson D. Refined characterisation of chromosome aberrations in tumours by multicolour banding and electronic mapping resources. Methods Cell Sci. 2001; 23; 23-28.
23. Veldman T, Vignon C, Schröck E, Rowley JD, Ried T. Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping. Nat. Genet. 1997; 15; 406-410.
24. Kearney L. Multiplex-FISH (M-FISH): technique, developments and applications. Cytogenet. Genome Res. 2006; 114; 189-198.
25. Lichter P, Joos S, Bentz M, Lampel S. Comparative genomic hybridization: uses and limitations. Semin. Hematol. 2000; 37; 348-357.
26. Bentz M, Dohner H, Werner CA et al. Identification of genetic imbalances in malignant lymphoma using comparative genomic hybridization. Stem Cells 1995; 13(Suppl. 3); 83-87.
27. Salaverria I, Bea S, Lopez-Guillermo A et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br. J. Haematol. 2008; 140; 516-526.
28. Seto M, Honma K, Nakagawa M. Diversity of genome profiles in malignant lymphoma. Cancer Sci. 2010; 101; 573-578.
29. Takeuchi I, Tagawa H, Tsujikawa A et al. The potential of copy number gains and losses, detected by array-based comparative genomic hybridization, for computational differential diagnosis of B-cell lymphomas and genetic regions involved in lymphomagenesis. Haematologica 2009; 94; 61-69.
30. Booman M, Szuhai K, Rosenwald A et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J. Pathol. 2008; 216; 209-217.
31. Schraders M, Jares P, Bea S et al. Integrated genomic and expression profiling in mantle cell lymphoma: identification of gene-dosage regulated candidate genes. Br. J. Haematol. 2008; 143; 210-221.
32. Wessendorf S, Barth TF, Viardot A et al. Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia 2007; 21; 2463-2469.
33. Thorns C, Bastian B, Pinkel D et al. Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: a matrix-based CGH approach. Genes Chromosom. Cancer 2007; 46; 37-44.
34. de Leeuw RJ, Davies JJ, Rosenwald A et al. Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum. Mol. Genet. 2004; 13; 1827-1837.
35. Lenz G, Wright GW, Emre NC et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl Acad. Sci. USA 2008; 105; 13520-13525.
36. Heinrichs S, Li C, Look AT. SNP array analysis in hematologic malignancies: avoiding false discoveries. Blood 2010; 115; 4157-4161.
37. Wang Y, Armstrong SA. Genome-wide SNP analysis in cancer: leukemia shows the way. Cancer Cell 2007; 11; 308-309.
38. Bea S, Salaverria I, Armengol L et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood 2009; 113; 3059-3069.
39. Schwindt H, Vater I, Kreuz M et al. Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma. Leukemia 2009; 23; 1875-1884.
40. O'Shea D, O'Riain C, Gupta M et al. Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood 2009; 113; 2298-2301.
41. Fitzgibbon J, Iqbal S, Davies A et al. Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia 2007; 21; 1514-1520.
42. Nielaender I, Martin-Subero JI, Wagner F, Martinez-Climent JA, Siebert R. Partial uniparental disomy: a recurrent genetic mechanism alternative to chromosomal deletion in malignant lymphoma. Leukemia 2006; 20; 904-905.
43. Haralambieva E, Schuuring E, Rosati S et al. Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions. Genes Chromosom. Cancer 2004; 40; 10-18.
44. Martin-Subero JI, Gesk S, Harder L, Grote W, Siebert R. Interphase cytogenetics of hematological neoplasms under the perspective of the novel WHO classification. Anticancer Res. 2003; 23; 1139-1148.
45. Wolff DJ, Bagg A, Cooley LD et al. Guidance for fluorescence in situ hybridization testing in hematologic disorders. J. Mol. Diagn. 2007; 9; 134-143.
46. Barrans SL, Evans PA, O'Connor SJ, Owen RG, Morgan GJ, Jack AS. The detection of t(14;18) in archival lymph nodes: development of a fluorescence in situ hybridization (FISH)-based method and evaluation by comparison with polymerase chain reaction. J. Mol. Diagn. 2003; 5; 168-175.
47. Vaandrager JW, Schuuring E, Raap T, Philippo K, Kleiverda K, Kluin P. Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes. Genes Chromosom. Cancer 2000; 27; 85-94.
48. Haralambieva E, Banham AH, Bastard C et al. Detection by the fluorescence in situ hybridization technique of MYC translocations in paraffin-embedded lymphoma biopsy samples. Br. J. Haematol. 2003; 121; 49-56.
49. Thompson CT, Gray JW. Cytogenetic profiling using fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH). J. Cell. Biochem. Suppl. 1993; 17G; 139-143.
50. Qian J, Bostwick DG, Takahashi S et al. Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histological sections from paraffin-embedded prostatic adenocarcinoma specimens. Am. J. Pathol. 1996; 149; 1193-1199.
51. Jordanova ES, Corver WE, Vonk MJ et al. Flow cytometric sorting of paraffin-embedded tumor tissues considerably improves molecular genetic analysis. Am. J. Clin. Pathol. 2003; 120; 327-334.
52. Jordanova ES, Riemersma SA, Philippo K, Giphart-Gassler M, Schuuring E, Kluin PM. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosom. Cancer 2002; 35; 38-48.
53. Mead GM, Barrans SL, Qian W et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008; 112; 2248-2260.
54. May PC, Foot N, Dunn R, Geoghegan H, Neat MJ. Detection of cryptic and variant IGH-MYC rearrangements in high-grade non-Hodgkin's lymphoma by fluorescence in situ hybridization: implications for cytogenetic testing. Cancer Genet. Cytogenet. 2010; 198; 71-75.
55. Nitta H, Zhang W, Kelly BD et al. Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models. Methods 2010; [epub ahead of print].
56. Stasik CJ, Nitta H, Zhang W et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica 2010; 95; 597-603.
57. van Rijk A, Svenstroup-Poulsen T, Jones M et al. Double-staining chromogenic in situ hybridization as a useful alternative to split-signal fluorescence in situ hybridization in lymphoma diagnostics. Haematologica 2010; 95; 247-252.
58. van Krieken JH, Langerak AW, Macintyre EA et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2007; 21; 201-206.
59. Langerak AW, Molina TJ, Lavender FL et al. Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2007; 21; 222-229.
60. Sandberg Y, Gastel-Mol EJ, Verhaaf B, Lam KH, van Dongen JJ, Langerak AW. BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. J. Mol. Diagn. 2005; 7; 495-503.
61. van Dongen JJ, Langerak AW, Bruggemann M et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17; 2257-2317.
62. Vaandrager JW, Schuuring E, Zwikstra E et al. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. Blood 1996; 88; 1177-1182.
63. De Boer CJ, Van Krieken JHJM, Schuuring E, Kluin PM. BCL1/cyclin D1 in malignant lymphoma. Ann. Oncol. 1997; 8(Suppl. 2); 109-117.
64. Andersen NS, Pedersen LB, Laurell A et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J. Clin. Oncol. 2009; 27; 4365-4370.
65. Liu H, Ye H, Ruskone-Fourmestraux A et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication 3. Gastroenterology 2002; 122; 1286-1294.
66. Farragher SM, Tanney A, Kennedy RD, Paul Harkin D. RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem. Cell Biol. 2008; 130; 435-445.
67. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am. J. Pathol. 2001; 158; 419-429.
68. Green TM, de Stricker K, Moller MB. Validation of putative reference genes for normalization of Q-RT-PCR data from paraffin-embedded lymphoid tissue. Diagn. Mol. Pathol. 2009; 18; 243-249.
69. van Maldegem F, de Wit M, Morsink F, Musler A, Weegenaar J, van Noesel CJ. Effects of processing delay, formalin fixation, and immunohistochemistry on RNA recovery from formalin-fixed paraffin-embedded tissue sections. Diagn. Mol. Pathol. 2008; 17; 51-58.
70. Gouas L, Goumy C, Veronese L, Tchirkov A, Vago P. Gene dosage methods as diagnostic tools for the identification of chromosome abnormalities. Pathol. Biol. 2008; 56; 345-353.
71. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403; 503-511.
72. Leich E, Hartmann EM, Burek C, Ott G, Rosenwald A. Diagnostic and prognostic significance of gene expression profiling in lymphomas. APMIS. 2007; 115; 1135-1146.
73. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry (vol 99, pg 409, 2002)88. Blood 2002; 99; 1108.
74. De Boer CJ, Schuuring E, Dreef EJ et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 1995; 86; 2715-2723.
75. Cheuk W, Wong KO, Wong CS, Chan JK. Consistent immunostaining for cyclin D1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody. Am. J. Surg. Pathol. 2004; 28; 801-807.
76. Stein H, Foss HD, Durkop H et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features 140. Blood 2000; 96; 3681-3695.
77. Mino-Kenudson M, Chirieac LR, Law K et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin. Cancer Res. 2010; 16; 1561-1571.
78. Ek S, Dictor M, Jerkeman M, Jirstrom K, Borrebaeck CA. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008; 111; 800-805.
79. Mozos A, Royo C, Hartmann E et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009; 94; 1555-1562.
80. Chen YH, Gao J, Fan G, Peterson LC. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod. Pathol. 2010; 23; 105-112.
81. Wang X, Asplund AC, Porwit A et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br. J. Haematol. 2008; 143; 248-252.
82. Fernandez V, Salamero O, Espinet B et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010; 70; 1408-1418.
83. Hailfinger S, Lenz G, Ngo V et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 2009; 106; 19946-19951.